Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Twist Bioscience Corp (TWST) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 8-K Quarterly results
Docs: "Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results"
05/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Twist Bioscience Appoints Robert Werner as Chief Accounting Officer SOUTH SAN FRANCISCO, Calif. – May 23, 2023 – Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “He will be an invaluable addition as Twist continues to gain market share and execute against our plan to achieve adjusted EBITDA breakeven for the core and biopharma businesses at the close of the fiscal fourth quarter of 2024.” “I have spent the enti..."
05/05/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
02/08/2023 8-K Quarterly results
02/03/2023 8-K Quarterly results
Docs: "Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results – Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 –"
11/18/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "BYLAWS OF TWIST BIOSCIENCE CORPORATION"
11/18/2022 8-K Quarterly results
11/15/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Twist Bioscience Addresses Misleading Short-Seller Report"
10/26/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Twist Bioscience Announces Promotions and Changes to Executive Leadership Team SOUTH SAN FRANCISCO, CA – April 21, 2022 — Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. In addition, Patrick Weiss will step down from his role as chief operating officer into a strategic advisor role for personal reasons, effective April 21, 2022, while a formal search is conducted for his replacement. “Tracey joined Twist through the acquisition of Abveris and quickly demonstrated her capability to lead dynamic organizations,” said Emi..."
03/09/2022 8-K Quarterly results
02/15/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "TWIST BIOSCIENCE CORPORATION 4,545,454 Shares of Common Stock Underwriting Agreement",
"Orrick, Herrington & Sutcliffe LLP The Orrick Building 405 Howard Street San Francisco, CA 94105-2669 +1-415-773-5700 orrick.com"
02/09/2022 8-K Quarterly results
02/04/2022 8-K Quarterly results
12/02/2021 8-K Quarterly results
11/22/2021 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities"
11/22/2021 8-K Quarterly results
Docs: "Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results -- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 -- -- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses -- -- Expect Revenue of $183M to $193M for Fiscal 2022 -- SOUTH SAN FRANCISCO, Calif. – November 22, 2021 – Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2021 ended September 30, 2021. “Fiscal 2021 was a transformational year for Twist, as we delivered significant revenue growth by diversifying and expanding our customer base in synbio and NGS, as wel..."
08/09/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/06/2021 8-K Quarterly results
Docs: "FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS · Orders: Total orders received for the third quarter of fiscal 2021 were $39.1 million, compared to $24.7 million for the same period of fiscal 2020. · Revenue: Total revenues were $35.0 million for the third quarter of fiscal 2021 compared to $21.2 million for the same period of fiscal 2020. · Cost of Revenues: Cost of revenues for the third quarter of fiscal 2021 was $20.9 million compared to $16.5 million for the same period of fiscal 2020. · Research and Development Expenses: Research and development expenses for the third quarter of fiscal 2021 were $19.8 million compared to $10.4 million for the same period of fiscal 2020. · Selling, General and Administrative Expenses: Selling, general and administrative..."
06/30/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/16/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
12/23/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Lease Agreement, between Twist Bioscience Corporation and PWII Owner, LLC"
12/04/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among Twist Bioscience Corporation, the selling stockholders named therein, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C",
"Opinion of Orrick, Herrington & Sutcliffe LLP"
11/23/2020 8-K Quarterly results
Docs: "Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results — Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 — — Strong Growth in Synthetic Biology, NGS Businesses — — Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 — — Expect Revenue of $110M to $118M for Fiscal 2021 — SOUTH SAN FRANCISCO, Calif. - November 23, 2020 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2020 ended September 30, 2020. “We ended our fiscal year with record revenue and orders against the backdrop of a global pandemic and si..."
08/06/2020 8-K Quarterly results
06/05/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, among Twist Bioscience Corporation, J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C",
"Opinion of Orrick, Herrington & Sutcliffe LLP"
05/07/2020 8-K Quarterly results
02/20/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy